A single blood draw that can search for more than 50 cancers sounds like a medical breakthrough. Galleri is now one step closer to formal approval in the United States, as per a report by USA Today.
An advisory panel to the Food and Drug Administration voted in favor of the test on September 23. The decision gave GRAIL, Galleri’s developer, an important regulatory victory.
